Get the Stockscreener App
37.22
0.57%
0.21
After Hours:
37.22
Qiagen Nv stock is traded at $37.22, with a volume of 2.06M.
It is up +0.57% in the last 24 hours and up +12.86% over the past month.
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2024 sales), followed by EMEA (33%), and the Asia-Pacific (15%).
See More
Previous Close:
$37.01
Open:
$37.355
24h Volume:
2.06M
Relative Volume:
1.00
Market Cap:
$7.68B
Revenue:
$2.10B
Net Income/Loss:
$402.17M
P/E Ratio:
19.23
EPS:
1.9357
Net Cash Flow:
$403.87M
1W Performance:
-1.40%
1M Performance:
+12.86%
6M Performance:
-17.31%
1Y Performance:
-21.56%
1-Day Range:
$37.15
$37.57
1-Week Range:
$36.69
$37.57
52-Week Range:
$32.53
$57.81
Qiagen Nv Stock (QGEN) Company Profile
Compare QGEN vs TMO, DHR, IDXX, A, WAT
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
QGEN
Qiagen Nv
|
37.22 | 7.63B | 2.10B | 402.17M | 403.87M | 1.9357 |
TMO
Thermo Fisher Scientific Inc
|
472.63 | 176.04B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
181.35 | 128.18B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
573.00 | 44.96B | 4.45B | 1.10B | 1.06B | 13.59 |
A
Agilent Technologies Inc
|
128.34 | 36.88B | 7.23B | 1.41B | 1.09B | 4.979 |
WAT
Waters Corp
|
360.54 | 35.13B | 3.77B | 449.25M | 240.68M | 7.8556 |
Qiagen Nv Stock (QGEN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-14-26 | Downgrade | Barclays | Overweight → Equal Weight |
| Mar-13-26 | Upgrade | Deutsche Bank | Hold → Buy |
| Jan-22-26 | Downgrade | Deutsche Bank | Buy → Hold |
| Dec-11-25 | Downgrade | Citigroup | Buy → Neutral |
| Jun-24-25 | Initiated | Barclays | Overweight |
| Apr-04-25 | Downgrade | Redburn Atlantic | Buy → Neutral |
| Feb-19-25 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jan-06-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-10-24 | Upgrade | Jefferies | Hold → Buy |
| Oct-17-24 | Downgrade | HSBC Securities | Buy → Hold |
| Jun-27-24 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Dec-19-23 | Initiated | Wells Fargo | Equal Weight |
| Dec-13-23 | Initiated | Wolfe Research | Peer Perform |
| Dec-07-23 | Upgrade | Goldman | Neutral → Buy |
| Sep-12-23 | Initiated | Robert W. Baird | Outperform |
| May-23-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-18-22 | Initiated | Morgan Stanley | Equal-Weight |
| Jan-18-22 | Upgrade | DZ Bank | Hold → Buy |
| Oct-15-21 | Resumed | Cowen | Market Perform |
| Oct-14-21 | Initiated | Redburn | Buy |
| Jul-14-21 | Downgrade | Kepler | Buy → Hold |
| Jun-03-21 | Initiated | Goldman | Neutral |
| Oct-06-20 | Resumed | BofA Securities | Buy |
| Sep-28-20 | Upgrade | Kepler | Hold → Buy |
| Aug-24-20 | Upgrade | Citigroup | Neutral → Buy |
| Aug-20-20 | Resumed | JP Morgan | Overweight |
| Aug-17-20 | Upgrade | Berenberg | Hold → Buy |
| Aug-14-20 | Upgrade | Deutsche Bank | Hold → Buy |
| Aug-14-20 | Upgrade | Exane BNP Paribas | Neutral → Outperform |
| Mar-04-20 | Downgrade | Berenberg | Buy → Hold |
| Jan-08-20 | Initiated | Wells Fargo | Equal Weight |
| Jan-07-20 | Initiated | Citigroup | Neutral |
| Dec-26-19 | Resumed | BofA/Merrill | Underperform |
| Nov-15-19 | Initiated | Stifel | Hold |
| Nov-14-19 | Upgrade | Evercore ISI | In-line → Outperform |
| Nov-14-19 | Upgrade | JP Morgan | Underweight → Overweight |
| Nov-14-19 | Upgrade | Kepler | Reduce → Hold |
| Oct-17-19 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Oct-09-19 | Downgrade | Kepler | Hold → Reduce |
| Oct-08-19 | Downgrade | Barclays | Overweight → Equal Weight |
| Oct-08-19 | Downgrade | Deutsche Bank | Buy → Hold |
| Oct-08-19 | Downgrade | JP Morgan | Neutral → Underweight |
View All
Qiagen Nv Stock (QGEN) Latest News
QIAGEN Bets Big on Digital PCR with Major QIAcuity Ecosystem Expansion - BioPharma APAC
QIAGEN Expands QIAcuity Gene Expression Portfolio to Drive dPCR Use - TradingView
QIAGEN Expands QIAcuity Gene Expression Portfolio to Accelerate Digital PCR Adoption Across Research and Biopharma - BioSpace
QIAGEN Enhances QIAcuity Gene for Research and Biopharma - World Business Outlook
Qiagen N.V. Expands Qiacuity Gene Expression Portfolio and Enhances Digital Pcr Ecosystem - marketscreener.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Qiagen N.V.QGEN - Eastern Progress
PTA-PVR: QIAGEN N.V.: Release according to Article 40, Section 1 of the WpHG - TradingView
Release according to Article 40, Section 1 of the WpHG - TradingView
Qiagen N.V. Stock (NL0012169213): Sector Check On Diagnostics Player - AD HOC NEWS
Qiagen N.V. Stock: In focus after the latest verified market update - AD HOC NEWS
A Look at Qiagen NV (QGEN) After 4.2% Gain -- GF Value $52.66 vs Price $37.75 - GuruFocus
Qiagen N.V. stock (NL0012169213): focus on molecular diagnostics and steady demand drivers - AD HOC NEWS
Former AdvaMedDx Board Chair Joins Bruker’s Governing Body - Medical Product Outsourcing
Qiagen N.V. stock (NL0012169213): Diagnostics player stays in focus after latest quarterly update - AD HOC NEWS
How Qiagen N.v. (QGEN) Affects Rotational Strategy Timing - Stock Traders Daily
Qiagen N.V. stock (NL0012169213): Diagnostic specialist updates investors after recent earnings - AD HOC NEWS
Evaluating Qiagen (NYSE:QGEN) After New Bundibugyo Ebolavirus Digital PCR Assays Catch Investor Attention - Sahm
Qiagen N.V. Common Shares (NY: QGEN - FinancialContent
Goldman Sachs Discloses 3.14% Voting Stake in QIAGEN - TipRanks
UBS reveals 3.04% voting stake in Qiagen after AFM filing - TipRanks
Qiagen reports 2.75% voting stake in its shares held by UBS Group - TipRanks
MFS reports 12.45M-share, 6.0% stake in QGEN (NYSE: QGEN) - Stock Titan
Qiagen (QGEN) Up 12.1% Since Last Earnings Report: Can It Continue? - Yahoo Finance
QIAGEN Business Breakdown and Growth Drivers for 2026 - qz.com
Is Qiagen’s New Bundibugyo Assays Strategy Quietly Reframing Its Infectious Disease Tools Story (QGEN)? - simplywall.st
Is It Too Late to Buy Qiagen NV (QGEN) After 3.0% Rally? GF Value Says Undervalued - GuruFocus
AlphaValue/Baader Europe Cuts Qiagen Price Target, Estimates Post FY26 Guidance Change - 富途牛牛
LVIP MFS International Growth Fund's Qiagen NV(LTS:0RLT) Holding History - GuruFocus
Qiagen N.V. stock (NL0012169213): Legal probe and Jefferies conference keep shares in focus - AD HOC NEWS
Qiagen N.V. stock (NL0012169213): Shares in focus after Jefferies conference appearance and law firm - AD HOC NEWS
Qiagen N.V. stock (NL0012169213): Deutsche Bank reiterates Buy rating with USD 43 target - AD HOC NEWS
Qiagen (QGEN) Q1 2026 Earnings Transcript - AOL.com
QIAGEN NV : Deutsche Bank keeps its Buy rating - marketscreener.com
Qiagen N.V. (QGEN) Presents at Deutsche Bank German Corporate ConferenceSlideshow (NYSE:QGEN) 2026-06-01 - Seeking Alpha
Evaluating Qiagen (QGEN) Valuation After Recent Short Term Share Price Recovery - Yahoo Finance
Qiagen N.V. (QGEN) Stock Analysis: Healthcare Innovator With Nearly 20% Upside Potential - DirectorsTalk Interviews
Qiagen N.V. stock (NL0012169213): steady after Q1 2026 update while analysts refine outlook - AD HOC NEWS
Qiagen N.V. stock (NL0012169213): shares steady after Q1 2026 update and ownership shift - AD HOC NEWS
UBS Discloses 2.45% Stake in Qiagen via AFM Notification - The Globe and Mail
Bank of America Discloses 3.15% Voting Stake in Qiagen - The Globe and Mail
Legal & General Group Plc Sells 40,221 Shares of Qiagen N.V. $QGEN - MarketBeat
Qiagen N.V. stock (NL0012169213): UBS stake disclosure and AFM voting rights notice keep insider own - AD HOC NEWS
QIAGEN’s Outlook Reset: Can Digital PCR And Sample Tech Offset QuantiFERON Weakness? - Smartkarma
Qiagen N.V. stock (NL0012169213): New Ebola research assays in focus as valuation metrics come into - AD HOC NEWS
Is QGEN Stock a Hold After the 2026 Outlook Cut and Q1 Miss? - TradingView
Qiagen N.V. stock (NL0012169213): Diagnostics group under scrutiny after investor investigation upda - AD HOC NEWS
Qiagen NV Bolsters Bundibugyo Ebola Research - Devdiscourse
QIAGEN Supports Infectious Disease Research and Surveillance Efforts for Bundibugyo Ebolavirus Outbreak - BioSpace
U.S. Sets Up Ebola Quarantine in Kenya - Devdiscourse
Qiagen Nv Stock (QGEN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.56%
0.44%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):